Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.
Antares’ lead precision oncology programme is expected to enter the clinic in 2026.
BioCrossroads' Vince Wong discusses how his state is looking to differentiate itself from its rivals.
RQ Bio’s lead asset, RQB01, is currently in IND-enabling studies.
The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.
Combotope will deploy its platform to discover antibodies, accompanied by a specific antibody characterisation data package.
